HKeyBio Launches Preclinical Evaluation Framework for Eosinophilic Disorders

The new platform targets the intricacies of type 2 inflammation, focusing on eosinophil recruitment and epithelial barrier dysfunction. By integrating disease modeling with multidimensional efficacy endpoints, the service aims to provide clearer data for candidates targeting pathways such as IL-4/IL-13, IL-5, TSLP, and the CCR3/eotaxin axis.

HKEY-ExE™ 1.0 functions through four primary modules: disease modeling, multidimensional efficacy assessment, biomarker analysis, and translational support. While eosinophilic esophagitis (EoE) has seen recent advancements, EgE and other non-esophageal disorders remain difficult to model due to the variability in affected sites like the colon or small intestine. HKeyBio’s approach allows researchers to adapt protocols based on specific molecule types and project objectives, ranging from histological tissue injury assessments to the quantification of inflammatory cytokines. The company, which boasts a team with two decades of experience in autoimmune drug development, intends for this framework to assist global developers in validating mechanisms earlier in the pipeline, providing a bridge between initial discovery and IND-enabling preparation.